ArticleInternational journal of molecular sciences2026
Cerebrospinal Fluid Sediments as a Novel Tool for Potential Biomarkers of Neurodegenerative Diseases.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cerebrospinal fluid (CSF) biomarkers for neurodegenerative diseases have been extensively studied over the years. However, CSF samples are routinely centrifuged, and the resulting sediment or pellet is typically discarded to remove cellular debris and high-density particles. This standard practice raises a critical question: Could these discarded sediments harbour potential biomarkers? The aim of the present study is to demonstrate that CSF sediments contain specific brain-derived components and thus to substantiate the possible presence of biomarkers within these sediments. To this end, we analysed post-mortem CSF samples of one patient with neuropathologically confirmed Alzheimer's disease (AD) and one patient with confirmed progressive supranuclear palsy (PSP). CSF pellets were studied using transmission and scanning electron microscopy techniques (TEM and SEM, respectively), along with compositional analysis through SEM combined with energy-dispersive X-ray spectroscopy (SEM-EDX), as well as immunofluorescence and histochemical analyses on semithin pellet sections. We observed that, among others, CSF pellets contain brain-derived structures such as wasteosomes and psammoma bodies. Furthermore, we also found disease-relevant proteins, including tau and Aβ42 in the AD sediment and tau in the PSP sediment. Although further studies are required, the study of CSF pellets could open new avenues for biomarker discovery in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.